Roger Jeffs

Roger A. Jeffs is the founder of Kriya Therapeutics, Inc., founded in 2019, where the title held is Vice Chairman.
Dr. Jeffs is also the founder of Bull City Select Investments LLC..
Dr. Jeffs is currently Chief Executive Officer & Director at Liquidia Corp.
since 2022, Independent Director at Axsome Therapeutics, Inc. since 2014, and Director at Albireo AB. Former positions include President, Co-Chief Executive Officer & Director at United Therapeutics Corp.
from 2015 to 2016; Associate Director-Clinical Research at Amgen, Inc. in 1998; Independent Director at Sangamo Therapeutics, Inc. from 2017 to 2019; Independent Director at Spyryx Biosciences, Inc.; Director at Sio Gene Therapies, Inc. from 2018 to 2019; Independent Director at Dova Pharmaceuticals, Inc. from 2017 to 2019; Independent Director at Albireo Pharma, Inc. from 2017 to 2022; Director at Roivant Sciences, Inc. from 2018 to 2019; Director at Evecxia, Inc. from 2016 to 2021; Director at Liquidia PAH LLC from 2018 to 2020; and Member-Clinical Research at Glaxo Wellcome, Inc. in 1995.
Education includes an undergraduate degree from Duke University conferred in 1984 and a doctorate from UNC School of Medicine conferred in 1991.